Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.
Name:
art%3A10.1186%2Fs12885-016-258 ...
Size:
848.1Kb
Format:
PDF
Description:
Open access full text article
Authors
Freeman, KarolineSaunders, Mark P
Uthman, Olalekan A
Taylor-Phillips, Sian
Connock, Martin
Court, Rachel
Gurung, Tara
Sutcliffe, Paul
Clarke, Aileen
Affiliation
Division of Health Sciences, Medical School, University of Warwick, Gibbet Hill Campus, Coventry, CV4 7AL, UKIssue Date
2016
Metadata
Show full item recordAbstract
Pharmacokinetic guided dosing of 5-fluorouracil chemotherapies to bring plasma 5-fluorouracil into a desired therapeutic range may lead to fewer side effects and better patient outcomes. High performance liquid chromatography and a high throughput nanoparticle immunoassay (My5-FU) have been used in conjunction with treatment algorithms to guide dosing. The objective of this study was to assess accuracy, clinical effectiveness and safety of plasma 5-fluorouracil guided dose regimen(s) versus standard regimens based on body surface area in colorectal cancer.Citation
Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review. 2016, 16:523 BMC CancerJournal
BMC CancerDOI
10.1186/s12885-016-2581-xPubMed ID
27456697Type
ArticleLanguage
enISSN
1471-2407ae974a485f413a2113503eed53cd6c53
10.1186/s12885-016-2581-x
Scopus Count
Collections
Related articles
- Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
- Authors: Freeman K, Connock M, Cummins E, Gurung T, Taylor-Phillips S, Court R, Saunders M, Clarke A, Sutcliffe P
- Issue date: 2015 Nov
- Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
- Authors: Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M
- Issue date: 2008 May 1
- Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
- Authors: Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E
- Issue date: 2012 Dec
- Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
- Authors: Kline CL, Schiccitano A, Zhu J, Beachler C, Sheikh H, Harvey HA, Mackley HB, McKenna K, Staveley-O'Carroll K, Poritz L, Messaris E, Stewart D, Sivik J, El-Deiry WS
- Issue date: 2014 Jun
- Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
- Authors: Ho YF, Lu WC, Chen RR, Cheng AL, Yeh KH
- Issue date: 2011 Mar